Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
PLoS One. 2014 Apr 16;9(4):e94756. doi: 10.1371/journal.pone.0094756. eCollection 2014.
To investigate the potential synergy of IL-7-driven T cell-dependent and TLR7-mediated B cell activation and to assess the additive effects of monocyte/macrophages in this respect.
Isolated CD19 B cells and CD4 T cells from healthy donors were co-cultured with TLR7 agonist (TLR7A, Gardiquimod), IL-7, or their combination with or without CD14 monocytes/macrophages (T/B/mono; 1 : 1 : 0,1). Proliferation was measured using 3H-thymidine incorporation and Ki67 expression. Activation marker (CD19, HLA-DR, CD25) expression was measured by FACS analysis. Immunoglobulins were measured by ELISA and release of cytokines was measured by Luminex assay.
TLR7-induced B cell activation was not associated with T cell activation. IL-7-induced T cell activation alone and together with TLR7A synergistically increased numbers of both proliferating (Ki67+) B cells and T cells, which was further increased in the presence of monocytes/macrophages. This was associated by up regulation of activation markers on B cells and T cells. Additive or synergistic induction of production of immunoglobulins by TLR7 and IL-7 was associated by synergistic induction of T cell cytokines (IFNγ, IL-17A, IL-22), which was only evident in the presence of monocytes/macrophages.
IL-7-induced CD4 T cell activation and TLR7-induced B cell activation synergistically induce T helper cell cytokine and B cell immunoglobulin production, which is critically dependent on monocytes/macrophages. Our results indicate that previously described increased expression of IL-7 and TLR7 together with increased numbers of macrophages at sites of inflammation in autoimmune diseases like RA and pSS significantly contributes to enhanced lymphocyte activation.
研究白细胞介素 7(IL-7)驱动的 T 细胞依赖性和 Toll 样受体 7(TLR7)介导的 B 细胞激活的潜在协同作用,并评估单核细胞/巨噬细胞在这方面的附加作用。
从健康供体中分离出 CD19 B 细胞和 CD4 T 细胞,与 TLR7 激动剂(TLR7A,格地喹酮)、IL-7 或它们的组合与或不与 CD14 单核细胞/巨噬细胞(T/B/单核细胞;1:1:0.1)共培养。通过 3H-胸腺嘧啶掺入和 Ki67 表达测量增殖。通过 FACS 分析测量激活标志物(CD19、HLA-DR、CD25)的表达。通过 ELISA 测量免疫球蛋白的释放,并通过 Luminex 测定法测量细胞因子的释放。
TLR7 诱导的 B 细胞激活与 T 细胞激活无关。单独的 IL-7 诱导的 T 细胞激活以及与 TLR7A 的协同作用均增加了增殖(Ki67+)B 细胞和 T 细胞的数量,而在单核细胞/巨噬细胞存在的情况下,这一数量进一步增加。这与 B 细胞和 T 细胞激活标志物的上调有关。TLR7 和 IL-7 协同诱导产生免疫球蛋白与协同诱导 T 细胞细胞因子(IFNγ、IL-17A、IL-22)有关,仅在单核细胞/巨噬细胞存在的情况下才明显。
IL-7 诱导的 CD4 T 细胞激活和 TLR7 诱导的 B 细胞激活协同诱导辅助性 T 细胞细胞因子和 B 细胞免疫球蛋白的产生,这严重依赖于单核细胞/巨噬细胞。我们的结果表明,在 RA 和 pSS 等自身免疫性疾病中炎症部位先前描述的 IL-7 和 TLR7 表达增加以及巨噬细胞数量增加显著有助于增强淋巴细胞激活。